For these reasons, we tested the MND-c.o.RAG1 lentiviral vector, that has been chosen for a phase I/II clinical trial to treat RAG1-SCID (10), in two murine models of CID, the Rag1F971L/F971L and the Rag1R972Q/R972Q mice, in order to assess the efficacy and safety of the treatment. Here, RAG1 is linked to combined immunodeficiency.